A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MASTERKEY232
- Sponsors Amgen
- 21 Mar 2018 This trial has been Discontinued in Germany according to European Clinical Trials Database record.
- 22 Jan 2018 Planned End Date changed from 4 Dec 2022 to 23 Jun 2023.
- 22 Jan 2018 Planned primary completion date changed from 23 Aug 2021 to 31 Oct 2021.